37 results
6-K
EX-99.1
GLPG
Galapagos NV
9 Nov 22
Current report (foreign)
4:05pm
in specific subpopulations, demonstrating Galapagos’ commitment to the RA patient and HCP community
Mechelen, Belgium; 8 November 2022, 22.01 CET … data at ACR which highlights our continued commitment to patients and the healthcare provider community, in particular initial data from our first
6-K
EX-99.1
GLPG
Galapagos NV
28 Mar 22
Jyseleca® approved in Japan for ulcerative colitis
1:50pm
that the EMA’s planned safety review may negatively impact acceptance of filgotinib more widely by patients, the medical community, and healthcare payors, as well
6-K
EX-99.1
GLPG
Galapagos NV
29 Nov 21
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
6:00am
topline results from the MANGROVE Phase 2 trial in the first half of 2023.
“We thank the ADPKD community for participating in the MANGROVE Phase 2 trial
6-K
EX-99.1
GLPG
Galapagos NV
11 Jun 19
Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients
6:05am
of Galapagos. "We look forward to learning about the trial results next year. The OA community eagerly awaits clinical evidence of a disease-modifying candidate
6-K
EX-99.1
GLPG
Galapagos NV
16 May 24
Current report (foreign)
8:11am
of the collaboration agreement, BCA will provide access to its extensive network of over 50 community blood centers in 43 states for Good
6-K
EX-99.1
a80 3wzjqis8z92z8
28 May 21
Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
6:00am
6-K
EX-99.1
22pwvq kq7cs
6 Oct 22
Current report (foreign)
5:11pm
6-K
EX-99.1
yi3nz7
7 Feb 22
Current report (foreign)
2:40pm
6-K
EX-99.1
j5q1rt9879hi
26 May 20
Gilead and Galapagos Announce Positive Topline Results of Phase 2B/3 Trial of Filgotinib In Moderately to Severely Active Ulcerative Colitis
6:10am
6-K
EX-99.1
gt7q2
31 May 22
Current report (foreign)
1:39pm
6-K
EX-99.1
y93xfahw1 0x
23 May 23
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
7:30am
6-K
EX-99.3
abcl3d 6nf7
11 Apr 22
Current report (foreign)
5:14pm
6-K
EX-99.1
efo8icm
4 Nov 22
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
4:57pm
6-K
EX-99.1
6qo7 s7la19
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
6-K
EX-99.1
fn6mk0z5b1rt27mvsufw
24 Feb 22
Galapagos 2021 results set stage for future growth
5:19pm
6-K
EX-99.1
y9crs77edvcuu2j
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.1
nmk5qkc
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.1
2n3pxbb6315 z1cj9blj
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
ncboz
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
6-K
EX-99.1
3hcz6c24ag9
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am